





INVESTOR PRESENTATION 3Q 2026

FORWARD-LOOKING STATEMENTS

During the course of this presentation, the Company may make projections and other forward-looking statements regarding future events or the future financial performance of the Company, including without limitation, statements regarding future operating results, growth opportunities and other statements that refer to Stereotaxis' plans, prospects, expectations, strategies, intentions and beliefs. These statements are subject to many risks and uncertainties that could cause actual results to differ materially from expectations. For a detailed discussion of risks and uncertainties that affect the Company's business and qualify the forward-looking statements made in this presentation, we refer you to the Company's periodic and other public filings filed with the SEC, including the most recently filed Forms 8-K, 10-Q and 10-K. The Company's projections and forward-looking statements are based on factors that are subject to change and therefore these statements speak only as of the date they are given. The Company assumes no obligation to update any projections or forward-looking statements. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities. Such an offer or solicitation, if made, will only be made pursuant to an offering memorandum and definitive subscription documents.



Pioneering **ENDOVASCULAR SURGICAL ROBOTICS**



Highly Differentiated Technology

Unique robotic solutions
for minimally invasive
endovascular surgery

Leadership In Large Markets

Only robotic technology in \$16B+
electrophysiology market;
Annual TAM >\$30B

Global Commercial Presence

150,000+ patients treated
100+ systems installed
20+ countries


Robust Clinical Value

500+ publications
Robust real-world value

Solid Financial Foundation

\$10M+ cash & no debt
Operations near breakeven

ROBOTICS TRANSFORMING SURGERY




Open Surgery

>5,000 Installed Robots
>500,000 Robotic Procedures/Year



Laparoscopic Surgery

>10,000 Installed Robots
>3,000,000 Robotic Procedures/Year



Endovascular Interventions



*ENDO VASCULAR ROBOTICS'
TIME IS NOW!*



Why Has Endovascular Robotics Lagged?

1

Challenging Anatomy

Small, Delicate, Tortuous Anatomy



2

Challenging Devices

Catheters are Flexible Instruments



TRANSFORMING CATHETER NAVIGATION

Traditional Catheters



Catheter controlled from the handle several feet from the patient's heart

1

Limited Precision, Stability & Reach

Moving the tip of a manual catheter requires force to be translated the length of the catheter

2

Rigid Catheter

Required rigidity of a manual catheter introduces inherent safety risks for patients

3

Radiation Exposure

Reliance on fluoroscopy for visualization places patients, physicians and staff at risk

ROBOTIC MAGNETIC NAVIGATION (RMN)



Direct control of the catheter tip using precise magnetic fields



Precision

1mm/1° precision unmatched by even the most skilled hands



Reach

Magnetic tip control allows navigation through complex anatomy that is otherwise unreachable



Stability & Safety

RMN catheters are atraumatic and magnetically held to tissue at forces limited to safe levels

ROBOTIC MAGNETIC NAVIGATION (RMN)

Robotic Magnetic Navigation System

External computer-controlled permanent magnets create a magnetic field within which a catheter with a magnetic tip can be precisely maneuvered.



Physician Cockpit

Physician sits at a computer control station, views procedure data on a large HD monitor, and uses a mouse/joystick to operate.





MEANINGFUL CLINICAL IMPACT & REAL-WORLD VALIDATION



Global
Robot Adoption

>100 Hospitals



Broad
Patient Care

>150,000 Patients



Attractive
Clinical Data

>500 Publications

PATIENT SAFETY & OUTCOMES

72%

Fewer Major Complications

6-8%

Improved ST & LT Efficacy

36%

Less Radiation Exposure

*Data on file with Stereotaxis and available at RoboticEP.com; from review of clinical literature comparing robotic to manual cardiac ablation

Enabling Advanced Patient Care



Dr. Burkhard Hügl
Neuwied, Germany

“With Stereotaxis we are able to address **all types of arrhythmias**... not only typical flutters or AV-node dependent dysrhythmia but also complex arrhythmias such as VT and AF.”



Dr. Peter Weiss
Phoenix, Arizona

“For ventricular arrhythmia, it really shines in terms of **ease of use**, **patient safety** and growing literature demonstrating **improved outcomes**.”



Dr. Dhanunjaya Lakkireddy
Kansas City, Missouri

“Robotics allows us to better address a range of complex arrhythmias that otherwise might not have been treated, **providing hope** to many patients who **otherwise would have had no options**.”




Prof. Sabine Ernst
London, United Kingdom

“For congenital heart disease patients, magnetic navigation is key. These anatomies are so variable and large that you need **absolute precision and control**. Stereotaxis makes procedures possible that would otherwise be too risky or simply not feasible.”



PHYSICIAN SAFETY & EXPERIENCE



! OCCUPATIONAL HAZARDS

Risks of the Manual Cath Lab:

85%
Left vs Right Sided
Brain Tumors



49%
Orthopedic Injury



50%
Cataracts



2.9X
Increased Infertility



ENHANCED EXPERIENCE

Benefits of Robotic Cath Lab:



Cognitive Skill Elevated
Enhanced environment and
information display




Full Control
Control over the entire procedure
at the physician's fingertips



Democratization of Skill
Reduced reliance on hand
skill with focus on therapy

Operate Seated, Unscrubbed & Outside Radiation
Enhance & Extend Your Career

KEY STRATEGIC TRANSFORMATIONS




Robotic Lab Constraints

High cost and burden to adopt a robot, including architectural planning, lab construction and an integrated x-ray.

Accessible Robot

Easily Accessible Without Construction




Catheter Dependency

Dependency on J&J for ablation catheter limited commercial freedom, innovation, and recurring revenue financial model.

Razorblade Model

Robust Ecosystem of Proprietary Catheters




Limited EP-Only Focus

A single-indication robot has more limited appeal to hospitals and a reduced commercial opportunity.

Multi-Specialty Platform

Robotic Platform Benefiting Multiple Indications



Aging Architecture

Limited innovation and an aged technological foundation without advanced digital capabilities

Digital Ecosystem

Bringing Digital Value to Robotics with Automation & AI



STRATEGIC TRANSFORMATION AT INFLECTION POINT

Accessible Robot

GenesisX: Initiating Commercialization Following FDA Clearance & CE Mark

- Shift from construction process to weekend install (no room shielding; simple power; smaller; lighter; reversible)
- Shortens sales cycle and increases opportunity set; enables alternative financial models (lease/placement)
- 2026 focus on establishing compatibility with various x-rays & demonstrating commercial clinical use

Razorblade Model

MAGiC Ablation Catheter & MAGiC Sweep HD Mapping Catheter

- Launching first Stereotaxis-owned ablation & robotic HD mapping catheters in Electrophysiology (EP)
- Shift from a single disposable to a portfolio of EP catheters (MAGiC, MAGiC Sweep, and Map-iT)
- Observing 5x increase in revenue/procedure with disposable sales of >\$5,000 per procedure
- In 2026 focused on ramping manufacturing and transitioning existing users to proprietary catheters

Multi-Specialty Platform

Acquisition of Robocath & Development of EMAGIN Vascular Devices

- Acquired Robocath 2Q2026 providing complementary mechanical robotic technology for IC/Neuro
- EMAGIN Guidewire & Catheter in regulatory phase; supports magnetic navigation through tortuous vasculature
- Shift from single-procedure to multi-indication platform robot with >\$25 Billion increased TAM

Digital Ecosystem

Launch of Synchrony Digital Operating Room System: Connectivity, Automation & AI



- Synchrony system launched following CE Mark and FDA Clearance in 2Q2026
- Digital cockpit for Stereotaxis robots & synergistic venture advancing connectivity & AI to any operating room
- Projecting \$3M in initial standalone revenue in 2026; \$1B+ TAM with attractive SaaS business model
- Key focus on AI efforts that enhance Operating Room Intelligence and Robotic Automation

**At an Inflection Point with Multiple Recent Regulatory Approvals,
New Product Launches, and Active Near-Term Pipeline**

INNOVATION DRIVING GROWTH

Primary Revenue Growth Drivers:

- Increased System Sales with Accessible Robot**
Shift from construction process to mobile robot with rapid installation
- Increased EP Catheter Revenue**
Shift from a single disposable to a portfolio of catheters in EP
- Multi-Specialty Platform Expansion Into IC/NI**
Expanding addressable markets beyond EP into cardiology and neuro
- Digital Operating Room**
New digital solution advancing connectivity & AI to the operating room



* Projections for 2026 reflect previously communicated guidance for the year. Current expectations related to the contributions from new products are subject to risks and uncertainties that could cause actual results to differ materially from expectations.

FOUR COMMERCIAL OPPORTUNITIES

Electrophysiology



\$15B+

TAM

8,000+ EP Labs Performing
Cardiac Ablation

-
2M Cardiac Ablation
Procedures Annually

-
\$5,000+ Average Disposable
Revenue Per Procedure

Interventional Cardiology



\$20B+


TAM

5M+ PCI Procedures
Annually

-
2M+ Peripheral Procedures
Annually

-
20,000+ IC Cath Labs

Neurointervention



\$5B

TAM

1M Neuro Procedures
Annually

-
Stroke Therapy a
Significant Unmet Need

Cath Labs



\$1B

TAM

20,000+ Cath Labs
Globally

-
Capital & SaaS
Commercial Model

**Stereotaxis' Technologies Synergistically Address
Multiple, Highly-Attractive, Large Independent Markets**

TECH LEADERSHIP & INNOVATION PIPELINE


Magnetic Robots



**Fully Mobile, Unobtrusive,
Interoperable, & Accessible Robots**

Interoperability with
Unmodified X-Rays
-
Wireless Battery-Powered
GenesisX

Mechanical Robots



**Performing the Full Range
of Activities Across EP/IC/NI**

Next-Gen Robocath System
Capable of Handling 5
Devices in Tandem

Advanced Catheters



**With a Matching Portfolio of
Advanced Interventional Devices**

Pulsed Field Ablation
Combined with MAGIC
-
Magnetic Guidewire &
Catheter for IC/NI
-
Continued EP Robotic
Catheter Innovation

Digital Surgery



**Enhanced with Intelligence,
Connectivity & Automation**

SynX Connectivity App
Premium Features
-
AI Intraoperative
Decision Support
-
Robotic Automation
for EP & IC/NI

**Leadership & Competence Across the Full Ecosystem of Key Technologies
Continued Advance of a Robust Innovation Pipeline**

GOVERNANCE & FINANCIAL PRUDENCE



Aligned Board & Leadership

Significant Shareholders
Stock Comp Plan at \$1-5B MC

Capital Efficient & Prudent

Low Cash Utilization
Significant Operating Leverage

Robust Existing Business

2025 Revenue \$32M
Grew 20% YoY

Clean Balance Sheet

\$10M+ Cash
No Debt

THANK YOU




Innovative Technology

- Highly Differentiated Approach for Endovascular Surgery
- Global Leadership in Endovascular Robotics



Proven Clinical Value

- Enables Therapy and Improves Patient Outcomes
- Extensive Real-World Clinical Validation



Solid Foundation

- Financial Prudence: Clean Balance Sheet & Near Breakeven
- Aligned Board, Management and Shareholders



Strong Growth Drivers

- Significant Innovations Now Contributing to Growth
- Large Growing Current and Future Markets

